Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.30    0.00 (0.00%)
Bid:
1.20
Ask:
1.40
Spread: 0.20 (16.667%)
Market Cap: £20.87m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Director/PDMR Shareholding

7 Oct 2013 08:29

RNS Number : 8582P
Epistem Holdings plc
07 October 2013
Β 

ο»Ώ

Β 

Β 

Epistem Holdings Plc ("Epistem" or the "Company")

Β 

Directors' Shareholdings

Β 

Epistem today provides an update regarding the Company's share investment plan, details of which were announced on 13 July 2009.

Β 

As a result of the subscription for Partnership Shares and the award of Matching Shares, the executive Directors each increased their beneficial interests in the Company by 228 ordinary shares of 1.5p each. These shares were acquired on 30th July 2013, 30th August 2013 and 27th September 2013 at prices of 583p, 560p and 383p respectively.

Following these transactions, the current beneficial interests of the executive Directors are set out below:

Β 

Ordinary Shares %

Β 

Matthew Walls 10,600 0.11%

Dr Catherine Booth 984,955 10.17%

Dr Jeffrey Moore 14,280 0.15%

John Rylands 194,853 2.01%

Β 

Β 

Β 

Β 

For further details please contact:

Β 

Epistem Plc

Matthew Walls, CEO +44 161 606 7258

John Rylands, Finance Director +44 161 606 7244

Β 

Peel Hunt LLP

James Steel /Vijay Barathan +44 20 7418 8900

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
RDSGRBDGRDGBGXR
Date   Source Headline
1st Aug 20137:00 amRNSTrading Update
1st Jul 20134:04 pmRNSDirector/PDMR Shareholding
29th May 20133:29 pmRNSHolding(s) in Company
15th Apr 20131:39 pmRNSHolding(s) in Company
8th Apr 20134:08 pmRNSDirector/PDMR Shareholding
26th Mar 20137:01 amRNSSenior Executive Incentive Package
26th Mar 20137:00 amRNSHalf Yearly Report
1st Mar 201310:06 amRNSNotice of Results
22nd Feb 20139:13 amRNSAdditional Listing
20th Feb 20139:39 amRNSHolding(s) in Company
20th Feb 20139:35 amRNSHolding(s) in Company
10th Jan 20134:36 pmRNSDirector/PDMR Shareholding
9th Jan 20132:26 pmRNSHolding(s) in Company
17th Dec 20126:13 pmRNSDirector/PDMR Shareholding
13th Dec 20123:24 pmRNSResult of AGM
10th Dec 20129:45 amRNSHolding(s) in Company
7th Dec 20121:00 pmRNSCash Placing
21st Nov 20128:18 amRNSAnnual Report & Accounts and Notice of AGM
25th Oct 201210:54 amRNSHolding(s) in Company
24th Oct 201212:19 pmRNSHolding(s) in Company
24th Oct 20129:51 amRNSHolding(s) in Company
16th Oct 20127:00 amRNSFinal Results
4th Oct 20123:55 pmRNSDirector/PDMR Shareholding
10th Sep 20123:19 pmRNSPreliminary Results Date
6th Aug 20127:00 amRNSPre-Close Trading Update
3rd Aug 201211:58 amRNSProfessor Chris Potten
27th Jul 20124:09 pmRNSDirector's Shareholding and Additional Listing
10th Jul 20129:17 amRNSDirector/PDMR Shareholding
5th Jul 20127:00 amRNSTuberculosis test gains CE-IVD registration
3rd Apr 20124:53 pmRNSDirector/PDMR Shareholding
27th Mar 20129:13 amRNSAdditional Listing
14th Mar 20127:00 amRNSHalf Yearly Report
5th Mar 20127:00 amRNSEpistem Signs TB Channel Partner Agreement
22nd Feb 20128:18 amRNSHolding(s) in Company
21st Feb 20127:00 amRNSNotice of Results
20th Feb 20126:28 pmRNSHolding(s) in Company
10th Feb 20127:00 amRNSHolding(s) in Company
10th Jan 20121:18 pmRNSDirector/PDMR Shareholding
19th Dec 20115:54 pmRNSDirectors' shareholdings and issue of equity
25th Nov 201112:00 pmRNSCash Placing
9th Nov 20117:00 amRNS2011 Annual Report and Accounts & Notice of AGM
11th Oct 20117:00 amRNSFinal Results
7th Oct 201112:43 pmRNSDirector/PDMR Shareholding
5th Oct 20117:00 amRNSHuman DNA Identification Collaboration
27th Sep 20117:00 amRNSGenedriveT passes first in-field Tuberculosis test
4th Aug 20117:00 amRNSPre Close Trading Update
30th Jun 201112:00 pmRNSDirector/PDMR Shareholding
28th Jun 20117:00 amRNSTuberculosis Diagnostic Collaboration
23rd Jun 20114:38 pmRNSHolding(s) in Company
19th May 20115:20 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.